Home Tags Generics

Tag: Generics

Competition Issues in the Canadian Pharmaceutical Industry

This article is part of a Chronicle. See more from this Chronicle Alan Gunderson, Nov 24, 2014 Health care is a very important sector within the...

“Product Hopping” on Both Sides of the Pond: A Survey of...

This article is part of a Chronicle. See more from this Chronicle Michael Frese, Ingrid Vandenborre, Julia York, Nov 24, 2014 In recent years, courts in...

Pharmaceutical Antitrust Complexity

This article is part of a Chronicle. See more from this Chronicle Michael Carrier, Nov 24, 2014 The pharmaceutical industry is unique in its complexity. Markets...

What’s Nexium After Actavis?

This article is part of a Chronicle. See more from this Chronicle Ankur Kapoor, Rosa Morales, Oct 29, 2014 As the first reverse-payment antitrust case to...

When Does Sharing Make Sense?: Antitrust & Risk Evaluation and Mitigation...

This article is part of a Chronicle. See more from this Chronicle Jan Rybnicek, Apr 29, 2014 There exists a new front in the battle to...

Defining “Payments”: The First Post-Actavis Battleground in Pharmaceutical Reverse Payments

This article is part of a Chronicle. See more from this Chronicle Lauren Battaglia, Apr 29, 2014 In June 2013, the Supreme Court ruled in FTC...

Courts’ Prescription for Reverse-Payment Settlements Still Unknown Almost a Year After...

This article is part of a Chronicle. See more from this Chronicle Ankur Kapoor, Rosa Morales, Apr 29, 2014 Nearly a year after the Supreme Court...

New Jersey District Court Limits Actavis To Cash Payments

This article is part of a Chronicle. See more from this Chronicle Donald Falk, Christopher Kelly, Apr 29, 2014 As with patent infringement litigation in many...

Pay-for-Delay

Fiona Scott Morton, Dec 20, 2013 This article lays out the economics of competition between branded and generic pharmaceuticals and its welfare consequences. I explain...

“Pay-for-Delay”: What Do We Disagree On?

Pierre Regibeau, Dec 20, 2013 Antitrust concerns about “pay-for-delay” patent settlements are based on two theories of harms, one that stresses the need for courts...

News

Antitrust Mix by CPI